Skip to main content
SpringerLink
Log in

Differenzialdiagnose der Transaminasenerhöhung bei rheumatischen Erkrankungen

Differential diagnosis of elevated liver transaminases in rheumatic diseases

  • CME Zertifizierte Fortbildung
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Zusammenfassung

Im Rahmen von Laborkontrollen von Patienten mit rheumatischen Erkrankungen fallen nicht selten erhöhte Lebertransaminasen auf. Unter rheumatologischen Gesichtspunkten sind die möglichen Ursachen dafür vielfältig. Störungen der Leberfunktion können Folge bestimmter rheumatologischer Erkrankungen, wie z. B. dem systemischen Lupus erythematodes, sein. Die primäre biliäre Zirrhose und die primär sklerosierende Cholangitis sind mit Erkrankungen aus dem rheumatologischen Formenkreis assoziiert. Auf der anderen Seite präsentieren hepatologische Erkrankungen, wie z. B. die Hepatitis C oder die autoimmune Hepatitis, rheumatologische Symptome. Die häufigste Ursache von Erhöhungen der Lebertransaminasen bei Rheumapatienten ist sicherlich die antirheumatische Therapie.

Abstract

During laboratory monitoring of patients with rheumatic diseases it is not uncommon to notice elevated liver transaminase levels. From a rheumatological perspective there are multiple causes for this. Liver dysfunction can be the result of certain rheumatological diseases, such as systemic lupus erythematosus. Primary biliary cirrhosis and primary sclerosing cholangitis are associated with rheumatic diseases. On the other hand, hepatological diseases, such as hepatitis C and autoimmune hepatitis show rheumatological symptoms. The most common cause of elevation of liver transaminase levels in rheumatic patients is without doubt the anti-rheumatic therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Cantor H, Dumont A (1969) Hepatic suppression of sensitization to antigen absorbed into the portal system. Nature 223:472–476

    Article  Google Scholar 

  2. Wiegard C, Lohse AW (2005) Leber und Rheuma. Z Rheumatol 64:26–31

    Article  CAS  PubMed  Google Scholar 

  3. Abraham S, Begum S, Isenberg D (2004) Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis 63:123–129

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Kadar J, Petrovicz E (2004) Adult-onset Stills disease. Best Pract Clin Rheumatol 18:663–676

    Article  Google Scholar 

  5. Van Hoek B (1996) The spectrum of liver disease in systemic lupus erythematosus. Nether J Med 46:244–253

    Google Scholar 

  6. Milan-Mon A, Porto JL, Novo C (1993) Hepatic infarction in a pregnant patient with the primary anti-phospholipid syndrome. Lupus 2:275

    Article  Google Scholar 

  7. Iwai M, Harada Y, Ishii M et al (2003) Autoimmune hepatitis in a patient with systemic lupus erythematosus. Clin Rheumatol 22:234–236

    Article  CAS  PubMed  Google Scholar 

  8. Czaja A (2005) Diverse manifestations and evolving treatments of autoimmune hepatitis. Minerva Gastroenterol Dietol 51:313–333

    CAS  PubMed  Google Scholar 

  9. Mayet W, Lohse AW (2013) Komorbidität rheumatologischer und hepatologischer Erkrankungen. Z Rheumatol 72:547–554

    Article  PubMed  Google Scholar 

  10. Tsianos E, Hoofnagle JH, Foc CPH (1989) Sjögrens syndrome in patients with primary biliary cirrhosis. Hepatology 11:730

    Article  Google Scholar 

  11. Gow P, Flemming KA, Chapman RW (2001) Primary sclerosing cholangitis associated with rheumatoid arthritis and HLA DR4: Is the association a marker of patients with progressive liver disease? J Hepatol 34:631–635

    Article  CAS  PubMed  Google Scholar 

  12. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA (1986) Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci U S A 83:1627–1631

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Liaw Y (1998) Hepatitis viruses under immunosuppressive agents. J Gastroenterol Hepatol 13:14–20

    Article  CAS  PubMed  Google Scholar 

  14. Manzano-Alonso M, Castellano-Tortajada G (2011) Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol 17:1531–1537

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Jobanputra P, Amarasena R, Maggs F (2008) Hepatotoxicity associated with sulfasalazine in inflammatory arthritis. BMC Musculoskel Dis 9:48

    Article  Google Scholar 

  16. Quintin E, Scoazec JY, Marotte H, Miossec P (2010) Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes. Arthritis Res Ther 12:R143

    Article  PubMed Central  PubMed  Google Scholar 

  17. Keyßer G (2011) Methotrexat-Toxizität. Mythen und Fakten. Z Rheumatol 70:108–113

    Article  PubMed  Google Scholar 

  18. Vassilopoulos D, Calabrese LH (2007) Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections. Curr Opin Rheumatol 19:619–625

    Article  PubMed  Google Scholar 

  19. Saag K, Teng GG, Patkar NM et al (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762–784

    Article  CAS  PubMed  Google Scholar 

  20. Kusumoto S, Tanaka Y, Mizokami M, Ueda R (2009) Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 90:13–23

    Article  CAS  PubMed  Google Scholar 

  21. Kusumoto S, Tanaka Y, Ueda R, Mizokami M (2011) Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol Hepatol 46:9–16

    CAS  Google Scholar 

  22. Kremer J, Koff R (1992) A debate: should patients with rheumatoid arthritis on methotrexate undergo liver biopsie? Semin Arthritis Rheum 2003:376

    Article  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. W.-J. Mayet gibt an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Zentrum für Innere Medizin, Nordwest-Krankenhaus Sanderbusch, Hauptstr., 26452, Sanderbusch, Deutschland

    W.-J. Mayet

Authors
  1. W.-J. Mayet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W.-J. Mayet.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mayet, WJ. Differenzialdiagnose der Transaminasenerhöhung bei rheumatischen Erkrankungen. Z. Rheumatol. 74, 137–145 (2015). https://doi.org/10.1007/s00393-014-1501-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-014-1501-1

Schlüsselwörter

Keywords

Search

Navigation